Pipeline
The only Radiopharmaceutical company achieving
successful commercialization of all new tracers in Korea
New Drug Development Strategy for Radiopharmaceuticals
Pipeline
FES
- Korea’s first Radiopharmaceutical diagnostic tracer for breast cancer in the market
- Medical imaging agent to detect metastatic breast cancer and differentiate the Estrogen receptor status
| Rights & Permissions / Sales | Acquire the rights for Korean domestic market and secure the overseas licensing rights | Drug classification | Diagnosis of breast cancer |
|---|---|---|---|
| Dates (Approval/Agreement) | Acquired NDA approval on Nov. 2019 | Remarks |
|
F-DOPA
- Diagnosis of brain tumors that are undetectable using FDG
- World’s first stable neutralization manufacturing technology
| Rights & Permissions / Sales | NDA in Korea and international licensing & commercialization | Drug classification | Diagnosis of brain tumor |
|---|---|---|---|
| Dates (Approval/Agreement) | Acquired NDA approval on Oct. 2019 | Remarks |
|
FACBC
- Korea’s first Radiopharmaceutical diagnostic tracer for prostate cancer in the market
- Open a new era for the diagnosis of metastatic and recurrent prostate cancer
| Rights & Permissions / Sales | For international market | Drug classification | Diagnosis of prostate cancer |
|---|---|---|---|
| Dates (Approval/Agreement) | June 24, 2019 – Exclusive licensing
agreement signed (Approved by US FDA and EMA) |
Remarks |
|
Solucin(177Lu-DOTATOC)
- Developed and launched therapeutic Radiopharmaceutical for the first time in the country
- Korea’s first Radiopharmaceutical therapy for Neuroendocrine tumor in the market
| Rights & Permissions / Sales | For approval in Korea | Drug classification | Gastroenteropancreatic Neuroendocrine Tumor Treatment |
|---|---|---|---|
| Dates (Approval/Agreement) | August 30, 2019 – Exclusive licensing agreement signed | Remarks |
|
.png)
